评估伴抑制物A型血友病小鼠中血小板基因治疗的可临床转化预处理方案
研究在已预免疫的重组人凝血因子VIII(FVIII)A型血友病(HA)小鼠中,比较白消安-氟达拉滨(Bu-Flu)与美法仑-氟达拉滨(Mel-Flu)预处理对血小板-FVIII基因治疗的效果,并以660厘戈瑞全身照射为对照。结果显示Bu-Flu而非Mel-Flu可实现成功基因治疗,所有接受Bu-Flu及660厘戈瑞的受体移植后嵌合率均>55%,出血表型被纠正,抑制物随时间消失,再攻击后未转导受体产生抑制物而转导受体未检测到抑制物,提示Bu-Flu预处理可建立免疫耐受。
要点
- Bu-Flu而非Mel-Flu预处理使2bF8基因治疗在伴抑制物HA小鼠中成功。
- Bu-Flu组与660厘戈瑞组受体移植后嵌合率均>55%,2bF8盒拷贝数与血小板-FVIII水平相当。
- Bu-Flu预处理下2bF8LV转导的预免疫HA小鼠建立免疫耐受,再攻击后未检测到抑制物。
核心结论
- Bu-Flu预处理可成功引入血小板-FVIII表达,在预免疫HA小鼠中恢复止血并诱导免疫耐受,提示该方案是伴抑制物HA基因治疗有前景的可临床转化策略。
研究设计与样本
- 研究用Bu-Flu与Mel-Flu对预免疫重组人FVIII的HA小鼠进行预处理,并以660厘戈瑞全身照射作为平行对照方案。
- 通过移植2bF8慢病毒(LV)转导的造血干细胞引入血小板-FVIII表达,采用荧光激活细胞分选、定量聚合酶链反应、FVIII检测和尾出血试验进行分析。
主要发现
- Bu-Flu而非Mel-Flu使2bF8基因治疗成功。
- Bu-Flu组与660厘戈瑞组所有受体在造血干细胞移植后均达到>55%嵌合率,2bF8盒拷贝数与血小板-FVIII水平相当。
- 2bF8LV转导受体出血表型被纠正。
- FVIII抑制物滴度随时间下降,两组抑制物消失时间相当。
- 滴度降至检测不到后以重组人FVIII再攻击,2bF8LV转导受体未检测到抑制物,而未转导移植对照小鼠全部产生抑制物。
关键数值与推荐
- Bu-Flu组与660厘戈瑞组所有受体移植后嵌合率均>55%。
- 2bF8LV转导受体在抑制物滴度降至检测不到后经重组人FVIII再攻击未检测到抑制物,而未转导移植对照小鼠全部产生抑制物。
临床怎么用
- 原文结论提示Bu-Flu预处理是伴抑制物HA基因治疗有前景的可临床转化策略,未给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Platelet gene therapy is effective in hemophilia A (HA) mice even with inhibitors. Fludarabine (Flu), along with busulfan (Bu) or melphalan (Mel), preconditioning has been shown to be highly effective for hematopoietic stem cell transplantation in the clinic. OBJECTIVES: To evaluate the efficacy of Bu-Flu and Mel-Flu preconditioning in platelet gene therapy of HA with inhibitors. METHODS: Bu-Flu and Mel-Flu were used to condition HA mice preimmunized with recombinant human factor (F)VIII. An optimal 660 centigray total body irradiation was used as a control regimen in parallel. Platelet-FVIII expression was introduced by transplantation of 2bF8 lentivirus (LV)-transduced hematopoietic stem cells. Animals were analyzed by fluorescence-activated cell sorting, quantitative polymerase chain reaction, FVIII assays, and tail bleeding tests. RESULTS: Bu-Flu, but not Mel-Flu, enabled successful 2bF8 gene therapy. All recipients achieved >55% chimerism post hematopoietic stem cell transplantation in both Bu-Flu and 660 centigray groups, with comparable copy numbers of 2bF8 cassette and the platelet-FVIII levels. The bleeding phenotype was rescued in 2bF8LV-transduced recipients. FVIII inhibitor titers declined with time, with comparable disappearance time of inhibitors between the 2 groups. When animals were rechallenged with recombinant human FVIII after the titers dropped to undetectable levels, no inhibitors were detected in 2bF8LV-transduced recipients. In contrast, all untransduced transplanted control mice produced inhibitors. These data demonstrate that immune tolerance was established in 2bF8LV-transduced primed HA mice under Bu-Flu conditioning. CONCLUSION: Bu-Flu preconditioning allows for successfully introducing platelet-FVIII expression to restore hemostasis and induce immune tolerance in primed HA mice, suggesting that this approach is a promising clinically translatable strategy for gene therapy of HA with inhibitors.
引用
- Chen Y, Li J, Schroeder JA, et al. Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors. J Thromb Haemost. 2024. PMID: 39127324. doi:10.1016/j.jtha.2024.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。